Sign In
Buy ALC
$64.22
-0.0600 (-0.0933%)
At Close: Jun 03, 2026
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Com
Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon
08:42am, Monday, 20'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the increasing public opposition to the proposed acquisition of STAAR Surgical C
Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
08:00am, Friday, 17'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical C
STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon
04:15pm, Thursday, 16'th Oct 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
01:36pm, Wednesday, 15'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent pro
Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
02:29pm, Tuesday, 14'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR�
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
01:11pm, Friday, 10'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical C
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
11:16am, Wednesday, 08'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advis
Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
08:00am, Wednesday, 08'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today sent the following letter to the shareholders of STAAR Surgical Company (“STAAR” or the �
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
11:25am, Tuesday, 07'th Oct 2025
CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1
Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
04:01pm, Monday, 06'th Oct 2025
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Com
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon
08:29am, Monday, 06'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical C
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
08:28am, Friday, 03'rd Oct 2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breach
